Cetrorelix

Cetrorelix

SCHEMBL61331

CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O

nearest known ligand 0.89

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GNRHR

The experimentally established mechanism targets of Cetrorelix. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
GNRHR known ✓ P30968 12/20 0.89
DRD1 P21728 1/20 0.89
OPRM1 P35372 1/20 0.89
MRGPRX2 Q96LB1 1/20 0.89
ABCB11 O95342 1/20 0.88

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cetrorelix SCHEMBL30883014 1.00 GNRHR (0.89) GNRHRDRD1OPRM1MRGPRX2ABCB11
Cetrorelix SCHEMBL30742606 1.00 GNRHR (0.89) GNRHRDRD1OPRM1MRGPRX2ABCB11
Cetrorelix SCHEMBL29887354 1.00 GNRHR (0.89) GNRHRDRD1OPRM1MRGPRX2ABCB11
Cetrorelix SCHEMBL24040297 1.00 GNRHR (0.89) GNRHRDRD1OPRM1MRGPRX2ABCB11
Cetrorelix SCHEMBL30882994 1.00 GNRHR (0.89) GNRHRDRD1OPRM1MRGPRX2ABCB11
Cetrorelix SCHEMBL24040283 1.00 GNRHR (0.89) GNRHRDRD1OPRM1MRGPRX2ABCB11
Cetrorelix SCHEMBL571416 1.00 GNRHR (0.89) GNRHRDRD1OPRM1MRGPRX2ABCB11
Cetrorelix SCHEMBL24040296 1.00 GNRHR (0.89) GNRHRDRD1OPRM1MRGPRX2ABCB11
Cetrorelix SCHEMBL30882997 1.00 GNRHR (0.89) GNRHRDRD1OPRM1MRGPRX2ABCB11
Cetrorelix SCHEMBL27794687 1.00 GNRHR (0.89) GNRHRDRD1OPRM1MRGPRX2ABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 18031 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114599384-B Stable parenteral dosage form of cetrorelix acetate SUN PHARMACEUTICAL INDUSTRIES LTD. (IN) 2026-05-26 CN claimed
CN-122070930-A Preparation composition of Qu Rui g of injection acetic acid and preparation method thereof 浙江和泽医药科技股份有限公司 2026-05-22 CN claimed
US-20260124148-A1 POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY BHAMIS RES LABORATORY PVT LTD (IN) 2026-05-07 US claimed
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 US claimed
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
US-20260096905-A1 IMPLANTABLE DRUG-DEVICE COMBINATIONS, AND RELATED METHODS OF TREATMENT PITUVIA THERAPEUTICS INC (US) 2026-04-09 US claimed
EP-4525938-B1 RADIOPHARMACEUTICAL COMPLEXES TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND ITS COMBINATIONS BAYER AG (DE) 2026-03-11 EP claimed
US-20260034192-A1 USE OF GNRH ANTAGONISTS IN MAMMALS TO SYNCHRONIZE FOLLICULAR WAVE EMERGENCE UNIV SASKATCHEWAN (CA) 2026-02-05 US claimed
US-12533321-B2 Polypeptide formulations for oral delivery Bhami's Research Laboratory, Pvt. Ltd. (IN) 2026-01-27 US claimed
US-12522572-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-01-13 US claimed
WO-1997027863-A1 COMBINED PHARMACEUTICAL PREPARATION CONTAINING LHRH-ANALOGOUS SUBSTANCES AND ANTI-ESTROGENS FOR TREATING GYNAECOLOGICAL DISORDERS SCHERING AKTIENGESELLSCHAFT (DE) 1997-08-07 WO claimed
US-5635161-A PULMONARY DELIVERY ABBOTT LABORATORIES (US) 1997-06-03 US claimed
EP-0771189-A1 INHALATION COMPOSITION ARZNEIMITTELWERK DRESDEN GmbH, FACHBEREICH PATENTE (DE) 1997-05-07 EP claimed
WO-1996040089-A2 AEROSOL DRUG FORMULATIONS CONTAINING VEGETABLE OILS ABBOTT LABORATORIES (US) 1996-12-19 WO claimed
EP-0732934-A1 LONG-ACTING INJECTION SUSPENSIONS AND A PROCESS FOR THEIR PREPARATION ASTA Medica Aktiengesellschaft (DE) 1996-09-25 EP claimed
WO-1996002231-A1 INHALATION COMPOSITION ASTA MEDICA AKTIENGESELLSCHAFT (DE) 1996-02-01 WO claimed
CN-1112019-A Novel process for the preparation of cetrorelix lyophilisate ASTA MEDICA AG (DE) 1995-11-22 CN claimed
WO-1995015767-A1 LONG-ACTING INJECTION SUSPENSIONS AND A PROCESS FOR THEIR PREPARATION ASTA MEDICA AKTIENGESELLSCHAFT (DE) 1995-06-15 WO claimed
EP-0657170-A1 Products for the application of high initial doses of cetrorelix and preparation of a combined package for use in treating diseases ASTA Medica Aktiengesellschaft (DE) 1995-06-14 EP claimed
EP-0611572-A2 Process to prepare a cetrorelix lyophilised composition ASTA Medica Aktiengesellschaft (DE) 1994-08-24 EP claimed